2004
Review of epidermal growth factor receptor biology
Herbst RS. Review of epidermal growth factor receptor biology. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: s21-s26. PMID: 15142631, DOI: 10.1016/j.ijrobp.2003.11.041.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSignal transduction pathwaysSmall molecule inhibitorsTransduction pathwaysSubsequent activationReceptor tyrosine kinasesEpidermal growth factor receptor biologyTyrosine kinase phosphorylationEGFR inhibitorsTyrosine kinase receptorsIntracellular portionGrowth factor receptorCommon pharmacologic approachesEGFR activityEGFR activationExtracellular domainTyrosine kinaseKinase phosphorylationKinase receptorsCognate ligandsTransmembrane glycoproteinReceptor biologyErbB familyTumor cell linesCellular proliferation
2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro J, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson R, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Journal Of Clinical Oncology 2002, 20: 110-24. PMID: 11773160, DOI: 10.1200/jco.2002.20.1.110.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntineoplastic AgentsApoptosisBiomarkersCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Dose-Response Relationship, DrugErbB ReceptorsFemaleGefitinibHumansKeratinocytesMaleMAP Kinase Signaling SystemMiddle AgedNeoplasmsQuinazolinesSkinStatistics, NonparametricTumor Suppressor ProteinsConceptsCancer patientsEpidermal growth factor receptor tyrosine kinase inhibitor ZD1839Tyrosine kinase inhibitor ZD1839Phase I clinical trialMaximum-tolerated doseDose-limiting toxicityEGFR activationReceptor-dependent processUnacceptable toxicityDefinitive efficacyPharmacodynamic assessmentSafety trialPharmacodynamic effectsClinical trialsKeratin plugsReceptor inhibitionMaturation markersSkin biopsiesPharmacodynamic studiesProliferation indexDose levelsOral ZD1839PatientsOptimal dosesZD1839